Welcome to our dedicated page for Bio-Path Hldgs SEC filings (Ticker: BPTH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Bio-Path Holdings filings document a clinical-stage biotechnology issuer focused on DNAbilize® liposomal delivery and antisense RNAi nanoparticle drug candidates. Material-event reports, exchange notices and late-filing notifications address governance, operating continuity, financing and capital-structure disclosures, and the common stock's registration or trading status.
The company's recent filings also record corporate-status and governance matters, including Nasdaq removal from listing, OTC Pink common stock disclosure, Wyoming domestication, creation of Series S Preferred stock, board and executive changes, a late Form 10-Q notification, and an operational pause instituted to conserve capital.
Bio-Path Holdings, Inc. filed a Form 12b-25 to notify the SEC and investors that its Form 10-Q for the quarter ended September 30, 2025 will be filed late. The company states it is still compiling the necessary information for the quarterly report and that all information has not yet been received due to a change in management. Bio-Path indicates it expects to file the Form 10-Q within the permitted grace period after the original due date.
Bio-Path Holdings (BPTH) filed an 8-K announcing a board change and financing plans. The Board accepted the resignation of Director Douglas Morris, delivered electronically on November 4, 2025 and accepted on November 13, 2025.
The company is seeking financing to support a planned turnaround that it anticipates will include updating its finance team, engaging new PCAOB auditors, hiring investment bankers to review its biotech portfolio for sale or partnerships, and pursuing strategic mergers and acquisitions. The company cautions that there can be no assurances of success. If capital cannot be raised, the company states there is substantial doubt about its ability to continue as a going concern and to remain listed on the OTC Markets or other public trading platforms.
Bio-Path Holdings (BPTH) announced leadership changes. On October 22, 2025, the Board appointed Vikram Grover as President, Chief Executive Officer, Chief Financial Officer, and a member of the Board. The Board also accepted the resignation of Douglas Morris as Interim CEO and Interim CFO; he remains on the Board. In addition, Paul Aubert resigned as a Director.
This consolidates executive leadership under one individual while maintaining board continuity through Mr. Morris’s continued service. The filing does not include financial results or strategic updates, focusing solely on governance and leadership transitions.
On 20–22 June 2025, Bio-Path Holdings, Inc. (BPTH) disclosed a sequence of leadership departures and an immediate operational shutdown driven by acute liquidity constraints, according to its Form 8-K filing.
Founder Peter H. Nielsen resigned from every executive position—President, Chief Executive Officer, Chief Financial Officer, Treasurer, Principal Accounting Officer—as well as Chairman and director roles. Directors Heath Cleaver and Aline Sherwood also stepped down; both stated their decisions were not the result of disagreements with the Company or Board.
The remaining directors appointed Douglas P. Morris as Chairman with no compensatory changes. Concurrently the Board instituted a company-wide operational pause, furloughing most employees and suspending the majority of drug-development activities to conserve capital while it searches for new financing.
The filing reiterates prior warnings: without additional capital, Bio-Path may have to scale back or eliminate development programs, dispose of assets on unfavorable terms, or proceed to liquidation and dissolution. There is no assurance of securing funding on acceptable terms, if at all.
Overall, the 8-K signals elevated going-concern risk, abrupt leadership vacuum and potential value erosion for shareholders.